Clinical Trial Detail

NCT ID NCT03925350
Title Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors California Pacific Medical Center Research Institute
Indications

melanoma

Therapies

Niraparib

Age Groups: adult senior

Additional content available in CKB BOOST